Drugs / CB-280
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04279769 | Jul 2020 → Nov 2021 | cystic fibrosis | Calithera Biosciences, Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CB-280 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04279769 ↗ |
| Action | Inhibit | “arginase inhibitor” NCT04279769 ↗ |
| Route | Oral | “CB-280, oral capsule administered twice daily at the assigned dose level for 14 days” NCT04279769 ↗ |